[{"data":1,"prerenderedAt":209},["ShallowReactive",2],{"$f10q1tdu8nuej3":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":55,"top_diseases":84,"top_companies":111,"key_results":137,"trends":197,"previous_editions":206,"comparison":142,"highlighted_classes":207},1,"aad-2026","AAD","aad","AAD Annual Meeting 2026",2026,"Dermatology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1896,581,119,{"Phase 1":17,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":20,"Phase 3":21},9,22,8,6,72,[23,27,30,33,36,39,43,46,48,51],{"name":24,"count":25,"share":26},"JAK1",71,12,{"name":28,"count":29,"share":17},"IL4R",50,{"name":31,"count":32,"share":19},"IL13RA1",49,{"name":34,"count":35,"share":20},"IL-17A",37,{"name":37,"count":38,"share":20},"RARG",32,{"name":40,"count":41,"share":42},"JAK2",26,4,{"name":44,"count":45,"share":42},"IL23A",25,{"name":47,"count":45,"share":42},"IL23R",{"name":49,"count":50,"share":42},"RXRA",24,{"name":52,"count":53,"share":54},"TNFA",18,3,[56,60,64,68,72,74,77,81],{"name":57,"count":58,"share":59},"Small molecules",354,61,{"name":61,"count":62,"share":63},"Monoclonal antibodies",166,29,{"name":65,"count":66,"share":67},"Bispecific antibodies",41,7,{"name":69,"count":70,"share":71},"Carbohydrate, lipid and polymer therapeutics",28,5,{"name":73,"count":41,"share":42},"Natural-product mixtures and botanicals",{"name":75,"count":76,"share":54},"Peptides",19,{"name":78,"count":79,"share":80},"Non-antibody therapeutic proteins",14,2,{"name":82,"count":83,"share":80},"Vaccines",13,[85,88,91,94,96,99,101,104,106,109],{"name":86,"count":87,"share":76},"atopic dermatitis (AD)",109,{"name":89,"count":90,"share":17},"psoriasis",51,{"name":92,"count":93,"share":19},"plaque psoriasis",47,{"name":95,"count":66,"share":67},"acne vulgaris",{"name":97,"count":98,"share":67},"alopecia areata",39,{"name":100,"count":35,"share":20},"hidradenitis suppurativa (HS)",{"name":102,"count":103,"share":42},"psoriatic arthritis (PsA)",23,{"name":105,"count":53,"share":54},"Vitiligo",{"name":107,"count":108,"share":54},"basal cell carcinoma (BCC)",15,{"name":110,"count":108,"share":54},"chronic idiopathic urticaria (CIU)",[112,116,118,121,123,125,127,130,133,135],{"name":113,"count":114,"share":115},"Pfizer",57,10,{"name":117,"count":29,"share":17},"Regeneron Pharmaceuticals",{"name":119,"count":120,"share":67},"AbbVie",38,{"name":122,"count":70,"share":71},"Johnson & Johnson",{"name":124,"count":70,"share":71},"Novartis",{"name":126,"count":18,"share":42},"Eli Lilly",{"name":128,"count":129,"share":54},"Roche",17,{"name":131,"count":132,"share":54},"Incyte",16,{"name":134,"count":108,"share":54},"UCB",{"name":136,"count":79,"share":80},"Merck",[138,146,152,158,164,170,176,183,189],{"title":139,"drug":140,"company":142,"phase":143,"disease":92,"finding":144,"url":145},"VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones",{"name":141,"slug":141},"guselkumab",null,"Phase 3","IGA0\u002F1 (clear\u002Fminimal) and PASI90 response rates improved through W48 and were maintained at ~70% through W100 in the guselkumab-randomized and placebo-guselkumab groups.","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F75354\u002FVISIBLE+Cohort+A+Guselkumab+Skin+Clearance+and+Patient-Reported+Outcomes+Across+Skin+and+Joint+Symptoms+Through+Week+100+in+Participants+With+Moderate-to-Severe+Plaque+Psoriasis+Across+All+Skin+Tones.pdf",{"title":147,"drug":148,"company":142,"phase":143,"disease":89,"finding":150,"url":151},"Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial",{"name":149,"slug":149},"tildrakizumab","mNAPSI 75 response rate to tildrakizumab increased from 25.5% at W28 to 41.2% at W52; 76.9% of W28 responders sustained response at W52.","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F72762\u002FEfficacy+and+safety+of+tildrakizumab+in+patients+with+moderate-to-severe+psoriasis+affecting+the+nails+A+multicenter+randomized+double-blind+placebo-controlled+Phase+3b+trial.pdf",{"title":153,"drug":154,"company":142,"phase":143,"disease":92,"finding":156,"url":157},"Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis",{"name":155,"slug":155},"icotrokinra","ICO demonstrated higher IGA 0\u002F1 response rates vs PBO at W16 (67.5% vs 9.2%); treatment effect (proportion difference: 57.9% [95%CI:53.8–61.6%]) was consistent across subgroups (range:51.8–64.2%).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F72984\u002FConsistency+of+Skin+Clearance+With+the+Targeted+Oral+Peptide+Icotrokinra+Results+From+a+Large+Pooled+Cohort+of+Phase+3+Study+Participants+With+Moderate-to-Severe+Plaque+Psoriasis.pdf",{"title":159,"drug":160,"company":142,"phase":143,"disease":92,"finding":162,"url":163},"Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis",{"name":161,"slug":161},"bimekizumab","At Year1, 55.8%\u002F57.4% bimekizumab-treated vs 26.7% ustekinumab-treated\u002F40.8% secukinumab-treated patients achieved remission.","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F73673\u002FBimekizumab+on-treatment+remission+as+defined+by+the+National+Psoriasis+Foundation+1-year+results+versus+ustekinumab+and+secukinumab+in+patients+with+moderate+to+severe+plaque+psoriasis.pdf",{"title":165,"drug":166,"company":142,"phase":143,"disease":86,"finding":168,"url":169},"Greater Achievement of Minimal Disease Activity With Abrocitinib Versus Dupilumab: An AHEAD Treat-to-Target Analysis of Patients With Moderate-to-Severe Atopic Dermatitis",{"name":167,"slug":167},"abrocitinib","Of patients receiving abrocitinib 100 or 200 mg monotherapy, 2.5% and 5.6% achieved MDA at Week 2 versus 0.0% receiving placebo; dose-dependent responses increased at Week 12 (100 mg: 20.7%; 200 mg: 35.7%).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F74631\u002FGreater+Achievement+of+Minimal+Disease+Activity+With+Abrocitinib+Versus+Dupilumab+An+AHEAD+Treat-to-Target+Analysis+of+Patients+With+Moderate-to-Severe+Atopic+Dermatitis.pdf",{"title":171,"drug":172,"company":142,"phase":143,"disease":102,"finding":174,"url":175},"Efficacy and safety of deucravacitinib vs placebo in patients with active psoriatic arthritis by concomitant methotrexate use: a pooled analysis of pivotal phase 3 studies",{"name":173,"slug":173},"deucravacitinib","Rates of AEs and SAEs through W16 were similar with deucravacitinib and placebo regardless of concomitant use of methotrexate (AEs: no, 64.6% vs 51.1%; yes, 59.3% vs 51.3%; SAEs: no, 2.3% vs 1.9%; yes, 1.6% vs 1.6%).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F75559\u002FEfficacy+and+safety+of+deucravacitinib+vs+placebo+in+patients+with+active+psoriatic+arthritis+by+concomitant+methotrexate+use+a+pooled+analysis+of+pivotal+phase+3+studies.pdf",{"title":177,"drug":178,"company":142,"phase":180,"disease":86,"finding":181,"url":182},"Robust Efficacy of APG777 in Atopic Dermatitis Regardless of Baseline Disease Severity: Results from the Phase 2 APEX Part A Study",{"name":179,"slug":179},"apg777","Phase 2","Treatment with APG777 was well-tolerated and led to an overall EASI-75 response rate of 74.7% (n=56\u002F75) at Week 16 (vs. 26.3% [n=10\u002F38] placebo; p\u003C0.001).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F74906\u002FRobust+Efficacy+of+APG777+in+Atopic+Dermatitis+Regardless+of+Baseline+Disease+Severity+Results+from+the+Phase+2+APEX+Part+A+Study.pdf",{"title":184,"drug":185,"company":142,"phase":180,"disease":100,"finding":187,"url":188},"Characterization of the IHS4 Response to Lutikizumab Treatment in Biologic-Naïve Patients With Moderate-to-Severe Hidradenitis Suppurativa (HS)",{"name":186,"slug":186},"lutikizumab","At Week 16, patients receiving lutikizumab showed improvement in percent change from baseline in AN count (-70.8%) and draining tunnels (-84.8%).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F72433\u002FCharacterization+of+the+IHS4+Response+to+Lutikizumab+Treatment+in+Biologic-Nave+Patients+With+Moderate-to-Severe+Hidradenitis+Suppurativa+HS.pdf",{"title":190,"drug":191,"company":142,"phase":194,"disease":92,"finding":195,"url":196},"A Randomized, Double-blind, Dose-Escalation, Placebo-Controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1139 for Patients with Moderate-to-Severe Plaque Psoriasis",{"name":192,"slug":193},"SHR-1139","shr-1139","Phase 1","Percentage change in PASI from baseline was -96.6% and -98.6% with SHR-1139 100 and 300 mg (vs 0 with placebo).","https:\u002F\u002Feposters.aad.org\u002Fs3\u002FAM2026\u002Fposter\u002F75013\u002FA+Randomized+Double-blind+Dose-Escalation+Placebo-Controlled+Phase+I+Study+Evaluating+the+Safety+Tolerability+Pharmacokinetics+and+Pharmacodynamics+of+SHR-1139+for+Patients+with+Moderate-to-Severe+Plaque+Psoriasis.pdf",{"summary":198,"bullets":200},[199],"Small molecules were the most frequent modality (61% of drug-linked abstracts). JAK1 was the most frequent target (12%). Atopic dermatitis (AD) was the most frequent disease (19%).",[201,202,203,204,205],"Pfizer had the largest company share (10% of drug-linked abstracts).","Bispecific antibodies accounted for 7% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (29%).","IL4R was the next most frequent target (9%).","Psoriasis was the next most frequent disease (9%).",[],[208],{"name":65,"count":66,"share":67,"previous_count":142,"previous_share":142,"direction":142},1793970603074]